[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-458167-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-458167-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","utility-of-the-swedish-anticholinergic-burden-scale-in-a-memory-clinic-setting-a-comparison-with-the-anticholinergic-cognitive-burden-scale","Utility of the Swedish Anticholinergic Burden Scale in a memory clinic setting - a comparison with the Anticholinergic Cognitive Burden scale","","Anticholinergic burden is linked to cognitive impairment, particularly in older adults with neurodegenerative diseases such as Alzheimer’s disease. This descriptive cross-sectional study evaluated drugs with anticholinergic properties and tested the utility of the Swedish Anticholinergic Burden Scale (Swe-ABS) in a memory clinic setting. Among 657 patients aged ≥50 in southern Sweden (Sep 2017–Sep 2021), Swe-ABS identified anticholinergic effects and distinguished high burden. Swe-ABS scores exceeded Anticholinergic Cognitive Burden (ACB) scores, with stronger differences in participants under 75 years.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/utility-of-the-swedish-anticholinergic-burden-scale-in-a-memory-clinic-setting-a-comparison-with-the-anticholinergic-cognitive-burden-scale/458167/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/utility-of-the-swedish-anticholinergic-burden-scale-in-a-memory-clinic-setting-a-comparison-with-the-anticholinergic-cognitive-burden-scale/458167.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study in a memory clinic setting?","Question",{"text":63,"@type":64},"The study aimed to explore the use of drugs with anticholinergic properties and assess the utility of the newly developed Swedish Anticholinergic Burden Scale (Swe-ABS) in a memory clinic setting.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many participants were included, and what was the approximate age range?",{"text":68,"@type":64},"In total, 657 individuals aged 50 years or older were included, with a mean age of 72.4 years.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the Swe-ABS results compare with the established ACB scale?",{"text":72,"@type":64},"Swe-ABS identified a higher proportion of participants with any anticholinergic effects and produced a significantly higher mean score than the ACB scale; the difference was stronger in individuals under 75 years.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},458167,1791101020,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nUtility of the Swedish Anticholinergic Burden Scale in a memory clinic setting:  \na comparison with the Anticholinergic Cognitive Burden scale  \nTanja Rube1􀀍, Elisabet Londos1,2 & Per Johansson3,4  \nAnticholinergic burden is associated with cognitive impairment, especially in older individuals with neurodegenerative disorders such as Alzheimer’s disease. The objective of the study was to explore the use of drugs displaying anticholinergic properties and examine the utility of the newly developed Swedish Anticholinergic Burden Scale (Swe-ABS) in a memory clinic setting. A descriptive crosssectional study, involving individuals ≥ 50 years of age attending a memory clinic in southern Sweden between September 2017 and September 2021. In total, 657 individuals, mean age 72.4 ± 9.0 years, 375 (57.1%) males, were included. The study population used 4805 medications at an average of 7.3 ± 4.3 per individual. A total of 448 (68.2%) participants used drugs with any anticholinergic effects identified with the Swe-ABS of whom 179 (27.2%) had a high anticholinergic burden (i.e., Swe-ABS ≥ 3). The corresponding figures for the established Anticholinergic Cognitive Burden (ACB) scale were 314 (47.8%) and 97 (14.8%) respectively. The mean Swe-ABS score was significantly higher than the mean ACB score (1.7 and 1.0; p \u003C 0.05) . Individuals \u003C 75 years had a significant higher Swe-ABS score and ACB score than individuals ≥ 75 years (Swe-ABS: \u003C 75 years: 1.94 ± 2.20 and ≥ 75 years: 1.50 ± 1.54; p \u003C 0.05; ACB: \u003C 75 years: 1.13 ± 1.57 and ≥ 75 years: 0.80 ± 1.14 p \u003C 0.05). Within the study population, a total of 64 drugs not listed in the Swe-ABS were identified. This study highlights the prevalence of drugs with anticholinergic effects among individuals presumably vulnerable to muscarinic antagonism. The SweABS, a risk scale for ascertaining the anticholinergic burden, seems to effectively identify a substantial proportion of drugs commonly used on the Swedish market. Trial [registration ClinicalTrials.gov](registration ClinicalTrials.gov), TRN: NCT03208569, Registration date: 27 June 2017.  \nKeywords Anticholinergic burden scale, Clinical pharmacy, Memory clinic, Muscarinic antagonists, Neurodegenerative disorders  \nAbbreviations  \nACB Anticholinergic Cognitive Burden scale  \nICD-10 International Classification of Diseases, 10th revision NBHW The Swedish National Board of Health and Welfare  \nOTC Over the counter  \nPIMs Potentially inappropriate medications  \nSwe-ABS Swedish Anticholinergic Burden Scale  \n1Cognitive Disorders Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden. 2Division of Clinical Geriatrics Department of Neurobiology, Care Sciences and Society, Karolinska Institute , Stockholm, Sweden. 3Department of Clinical Sciences , Lund University , Helsingborg, Sweden. 4Department of Internal Medicine , Sahlgrenska Academy University of Gothenburg , Gothenburg , Sweden. 􀀍 [email: tanja.rube@med.lu.se](email: tanja.rube@med.lu.se)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nThe inappropriateness of using drugs with significant anticholinergic effects (i.e., muscarinic cholinergic antagonists) in the treatment of older people has been known for decades1. This applies especially to individuals suffering from Alzheimer’s disease due to impaired cholinergic neurotransmission2. It has been suggested that the use of drugs with anticholinergic effects should be regarded as a potential modifiable risk factor for cognitive decline3.  \nThe Swedish National Board of Health and Welfare (NBHW) has published quality indicators concerning potentially inappropriate medications (PIMs) for older people. They include long-acting benzodiazepines, tramadol, propiomazine, codeine, and drugs with anticholinergic effects, and are restricted to drugs with significant anticholinergic effects4,5. However, there are drugs display","cbCaieQzjdptBQOb","https://ap.wps.com/l/cbCaieQzjdptBQOb","pdf",1425409,"English","# Background and rationale\n## Anticholinergic burden and cognitive impairment\n## Quality indicators and anticholinergic cumulative effects\n# Risk scales for anticholinergic burden\n## Swedish Anticholinergic Burden Scale (Swe-ABS)\n## Anticholinergic Cognitive Burden (ACB) scale\n# Study design and participants\n## Descriptive cross-sectional setting\n## Medication use and identification of anticholinergic effects\n# Results and interpretation\n## Prevalence of anticholinergic effects\n## Comparison of Swe-ABS and ACB scores\n## Unlisted drugs and implications","[{\"question\":\"What was the main objective of the study in a memory clinic setting?\",\"answer\":\"The study aimed to explore the use of drugs with anticholinergic properties and assess the utility of the newly developed Swedish Anticholinergic Burden Scale (Swe-ABS) in a memory clinic setting.\"},{\"question\":\"How many participants were included, and what was the approximate age range?\",\"answer\":\"In total, 657 individuals aged 50 years or older were included, with a mean age of 72.4 years.\"},{\"question\":\"How did the Swe-ABS results compare with the established ACB scale?\",\"answer\":\"Swe-ABS identified a higher proportion of participants with any anticholinergic effects and produced a significantly higher mean score than the ACB scale; the difference was stronger in individuals under 75 years.\"}]","Utility of the Swedish Anticholinergic Burden Scale in a memory clinic setting - a comparison with the Anticholinergic Cognitive Burden scale | PDF",1790751890,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/6f48a3ff7436412537855af02b9b13ed.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b3298ed89191e52b02f81e42a0ac8790.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/51ebab94a1acb3efb1ef77858af8fcc9.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b395b2c985d95d8ca14687becc7ce390.webp",980,1287]